• Explore /
  • Poster
  • / A first-in-human phase I study of MORAb-004 (M4), a humanized monoclonal antibody recognizing endosialin (TEM-1), in patients with solid tumors.

A first-in-human phase I study of MORAb-004 (M4), a humanized monoclonal antibody recognizing endosialin (TEM-1), in patients with solid tumors.

Abstract Poster

Authors

null

Luis A. Diaz Jr.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD

Luis A. Diaz Jr., Nilofer Saba Azad , Mrinal M. Gounder , Christina Marie Coughlin , Jean Fishel , Daniel O'Shannessy , Luigi Grasso , Jason Wustner , Jagadeesh Aluri , Jeff Parno , Richard D. Carvajal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics - Experimental Therapeutics

Track

Developmental Therapeutics

Sub Track

New Targets, New Technologies

Clinical Trial Registration Number

NCT00847054

Citation

J Clin Oncol 30, 2012 (suppl; abstr 3016)

DOI

10.1200/jco.2012.30.15_suppl.3016

Abstract #

3016

Poster Bd #

8

Abstract Disclosures

Similar Posters

Poster

2019 ASCO Annual Meeting

Phase 1 with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors.

Phase 1 with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors.

First Author: Maria Pia Morelli

First Author: Soohyeon Lee

First Author: Toshio Shimizu

First Author: Sara A. Hurvitz